ProtTech Inc.


	Platform Technology Neoantigen Discovery and Cancer Vaccine Development Based on ProtTech’s cutting-edge mass spectrometry technique, ProtTech has developed the MHC peptidomics technology platform to De Novo sequence MHC peptide ligands and identify neoantigens without NGS DNA sequencing. This approach is capable of identifying neoantigens from both coding and non-coding regions of the human genome, as well as from the genomes of many human viruses. More ...
	Protein Reagents Meganetic Nano Beads Purification Media Immobilized Enzyme mAb Magnetic Beads Enzymes Tool Enzymes Protease mRNA Capping Enzyme Systems Others Monoclonal antibody Anti Cell Factor mAb Anti CD molecules mAb Anti Virus Protein mAb Other mAb FITC antibody biotin-conjugated antibody Cell Factor Interleukin (IL) Growth Factors Interferon (IFN) Others
	Protein Services Antibody De Novo Sequencing With our state-of-the-art antibody de novo sequencing technology, we assure our clients of 100% accuracy in the delivered antibody sequences... More ... Protein Characterization complete analysis of protein primary structure, N- and C-terminals, disulfide bond linkage, etc… More ... Protein Identification & Analysis Ultra-sensitive NanoLC-MS technique to identify proteins from the gel, solution or complex mixture, etc… Our turn around time is five business days. More ... Protein Mutation & Sequence Variant Analysis Analyzing protein mutations to obtain complete sequence of a mutated protein… More ... Nanobody Discovery Service ProtTech has developed a novel AT-fusion platform (patent pending) to increase the in vivo half life of cell signaling proteins and nanobodies for therapeutic applications. More ...